RT Journal Article
SR Electronic
T1 Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials
JF CMAJ Open
JO CMAJ
FD Canadian Medical Association
SP E594
OP E602
DO 10.9778/cmajo.20180111
VO 6
IS 4
A1 Jennifer R. Donnan
A1 Catherine A. Grandy
A1 Eugene Chibrikov
A1 Carlo Marra PharmD
A1 Kris Aubrey-Bassler
A1 Karissa Johnston
A1 Michelle Swab
A1 Jenna Hache
A1 Daniel Curnew
A1 Hai Nguyen
A1 John-Michael Gamble
YR 2018
UL http://www.cmajopen.ca/content/6/4/E594.abstract
AB Background: The sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel group of drugs for treatment of type 2 diabetes mellitus. We investigated whether there is a dose–response relation between SGLT2 inhibitors and urinary tract infections (UTIs) in patients with type 2 diabetes, relative to other diabetes therapies or placebo.Methods: We conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) of SGLT2 inhibitors in patients with type 2 diabetes. We searched 6 databases and the reference lists of key papers. We included studies with placebo or active antidiabetic comparators that reported the outcome of UTI, and established thresholds for high and low doses of SGLT2 inhibitors. We used a random-effects model to estimate the pooled effect estimates and 95% credible intervals.Results: We screened 2418 citations and included 105 references for studies of 8 unique SGLT2 inhibitors, representing 60 082 individuals (with a total of 4348 UTIs). Most mixed-treatment comparisons showed no significant difference in risk of UTI, with the exception of high-dose dapagliflozin (≥ 10 mg) compared with placebo (odds ratio [OR] 1.30, 95% credible interval 1.09–1.57), with active comparators (OR 1.44, 95% credible interval 1.15–1.79), with empagliflozin at both low (OR 1.30, 95% credible interval 1.04–1.60) and high (OR 1.39, 95% credible interval 1.12–1.72) doses, and with low-dose ertugliflozin (OR 1.43, 95% credible interval 1.01–2.01). When the analysis was restricted to RCTs with a low risk of bias, the results were nonsignificant.Interpretation: Current RCT evidence does not suggest a dose–response relation between most SGLT2 inhibitors and UTIs, with the exception of dapagliflozin. Further research is needed to quantify the relation between SGLT2 inhibitors and more serious infections.Trial registration: PROSPERO registration no. CRD42016038715.